Lifecore Biomedical
LFCR
Lifecore Biomedical (LFCR) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.16
- EPS estimate
- −$0.29
- EPS surprise
- +44.83%
- Revenue surprise
- +7.89%
- Revenue
- $35.7M
- Revenue estimate
- $33.1M
- Reported
- Aug 5, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | −$0.29 | −$0.16 | +44.83% | $35.7M | SEC |
| Q1 2026 | May 6, 2026 | −$0.29 | −$0.43 | −48.28% | $23.2M | SEC |
| Q4 2025 | Mar 16, 2026 | −$0.29 | −$0.16 | +44.83% | $35.7M | SEC |
| Q2 2025 | Jan 2, 2025 | −$0.29 | −$0.16 | +44.83% | $35.7M | SEC |
| Q4 2023 | Aug 31, 2023 | −$0.12 | −$0.16 | −33.33% | $37.9M | SEC |
| Q3 2023 | Jun 1, 2023 | −$0.06 | $0.40 | +766.67% | $35.7M | SEC |
| Q2 2023 | Mar 16, 2023 | −$0.21 | $0.39 | +285.71% | $30.1M | SEC |
| Q1 2023 | Oct 6, 2022 | −$0.39 | −$0.35 | +10.26% | $24.5M | SEC |
| Q4 2022 | Aug 10, 2022 | −$0.45 | −$1.19 | −167.42% | $31.5M | SEC |
| Q3 2022 | Apr 5, 2022 | −$0.18 | −$1.33 | −638.89% | $27.6M | SEC |
| Q2 2022 | Jan 5, 2022 | −$0.21 | −$0.42 | −100.00% | $38.8M | SEC |
| Q1 2022 | Sep 29, 2021 | −$0.18 | −$0.41 | −134.29% | $43.4M | SEC |
| Q4 2021 | Jul 28, 2021 | −$0.03 | −$1.24 | −4409.09% | $47.6M | SEC |
| Q3 2021 | Apr 7, 2021 | $0.01 | −$0.43 | −4400.00% | $53.1M | SEC |
| Q2 2021 | Jan 6, 2021 | −$0.08 | −$1.30 | −1577.42% | $129.5M | SEC |
| Q1 2021 | Oct 6, 2020 | −$0.15 | −$0.32 | −116.22% | $128.8M | SEC |
| Q4 2020 | Aug 11, 2020 | −$0.02 | −$0.10 | −525.00% | $139.8M | SEC |
| Q3 2020 | Mar 31, 2020 | $0.02 | −$0.19 | −975.58% | $137.8M | — |
| Q2 2020 | Jan 2, 2020 | $0.01 | −$0.45 | −5521.69% | $130.9M | — |
| Q1 2020 | Oct 1, 2019 | −$0.13 | −$0.38 | −188.53% | $135.6M | — |
Quarterly revenue
Frequently asked questions
When did Lifecore Biomedical (LFCR) last report earnings?
Lifecore Biomedical last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did LFCR beat earnings estimates?
Yes. Lifecore Biomedical reported EPS of −$0.16 for Q2 2026 against a −$0.29 estimate — a 44.83% beat.
How much revenue did LFCR report last quarter?
Lifecore Biomedical reported $35.7M in revenue for Q2 2026, against a consensus estimate of $33.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.